Fate Therapeutics (FATE) Non-Current Assets (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Non-Current Assets came in at $105.4 million in Q1 2026, down 29.95% YoY from $150.5 million in Q1 2025, and down 4.39% on a QoQ basis from $110.2 million in Q4 2025.
Fate Therapeutics (FATE) Non-Current Assets (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Non-Current Assets data on file, last reported at $105.4 million in Q1 2026.
- Quarterly Non-Current Assets fell 29.95% year-over-year to $105.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $479.3 million (down 30.87% YoY) and the FY2025 annual result came in at $110.2 million, down 25.91% from the prior year.
- Non-Current Assets eased to $105.4 million in Q1 2026, from $110.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $259.3 million in Q1 2022 to a low of $105.4 million in Q1 2026.
- A 5-year average of $174.8 million and a median of $179.6 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets advanced 8.75% — and 2025, when it plunged 33.71%.
- Tracing FATE's Non-Current Assets over 5 years: stood at $203.5 million in 2022, then dropped by 14.16% to $174.7 million in 2023, then retreated by 14.82% to $148.8 million in 2024, then fell by 25.91% to $110.2 million in 2025, then retreated by 4.39% to $105.4 million in 2026.
- The last three Non-Current Assets figures came in at $105.4 million (Q1 2026), $110.2 million (Q4 2025), and $122.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 105.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 105.39 Mn |
| Dec 31, 2025 | 110.23 Mn |
| Sep 30, 2025 | 122.42 Mn |
| Jun 30, 2025 | 141.24 Mn |
| Mar 31, 2025 | 150.45 Mn |
| Dec 31, 2024 | 148.79 Mn |
| Sep 30, 2024 | 184.68 Mn |
| Jun 30, 2024 | 209.43 Mn |
| Mar 31, 2024 | 175.52 Mn |
| Dec 31, 2023 | 174.68 Mn |
| Sep 30, 2023 | 179.61 Mn |
| Jun 30, 2023 | 192.58 Mn |
| Mar 31, 2023 | 192.45 Mn |
| Dec 31, 2022 | 203.49 Mn |
| Sep 30, 2022 | 214.02 Mn |
| Jun 30, 2022 | 207.90 Mn |
| Mar 31, 2022 | 259.31 Mn |
| Dec 31, 2021 | 288.04 Mn |
| Sep 30, 2021 | 290.86 Mn |
| Jun 30, 2021 | 302.40 Mn |